102 results on '"Horowitz, Netanel A."'
Search Results
2. Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL—a matched cohort analysis
3. Association between IgG antibody levels and adverse events after first and second Bnt162b2 mRNA vaccine doses
4. A prediction model for central venous catheter-related thrombosis in patients with newly-diagnosed acute myeloid leukemia: A derivation cohort analysis
5. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial
6. BST-236, a novel cytarabine prodrug for patients with acute leukemia unfit for standard induction: a phase 1/2a study
7. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study
8. An international multicenter study comparing COVID‐19 omicron outcomes in patients with hematological malignancies treated with obinutuzumab versus rituximab.
9. Which patients should I transplant with acute lymphoblastic leukemia?
10. A phase 2 study of ibrutinib maintenance following first‐line high‐dose methotrexate‐based chemotherapy for elderly patients with primary central nervous system lymphoma.
11. Chronic lymphocytic leukemia cells acquire regulatory B-cell properties in response to TLR9 and CD40 activation
12. Heparanase-neutralizing antibodies attenuate lymphoma tumor growth and metastasis
13. Clonal Myeloid Dysplasia Following CAR T-Cell Therapy: Chicken or the Egg?
14. Non-Hodgkin lymphomas in pregnancy: Tackling therapeutic quandaries
15. Thrombosis in Pregnant Women with Hematological Malignancies: A Case-Based Review.
16. In chronic lymphocytic leukemia, activation of the thrombopoietin receptor promotes T‐cell inhibitory properties, contributing to immunosuppression.
17. Reproductive organ involvement in non-Hodgkin lymphoma during pregnancy: a systematic review
18. Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients
19. The role of additional chemotherapy prior to autologous HCT in patients with relapse/refractory DLBCL in partial remission—A retrospective multicenter study.
20. Real‐world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study.
21. PL-25 Mechanisms coupling thrombomodulin to tumor dissemination
22. Clinical features, therapy patterns, outcomes and prognostic factors of solitary plasmacytomas: a report of the Israeli Myeloma Study Group.
23. A 14-Year Experience in the Management of Patients with Acquired Immune Thrombotic Thrombocytopenic Purpura in Northern Israel: Rituximab Adjuvant Therapy in Patients with Refractory and Relapsed Disease Is Both Effective and Cost Beneficial
24. Author response: Precise staging of lymphoma duringpregnancy using MRI is not always crucial
25. An update on the management of hematologic malignancies in pregnancy
26. Bortezomib-induced peripheral neuropathy is related to altered levels of brain-derived neurotrophic factor in the peripheral blood of patients with multiple myeloma
27. Eradication of carbapenem-resistant Enterobacteriaceae gastrointestinal colonization with nonabsorbable oral antibiotic treatment: A prospective controlled trial
28. Dose-adjusted EPOCH-R is not superior to sequential R-CHOP/R-ICE as a frontline treatment for newly diagnosed primary mediastinal B-cell lymphoma: Results of a bi-center retrospective study.
29. Attenuated humoral immune response following anti‐SARS‐CoV‐2 vaccine in heavily pretreated patients with multiple myeloma and AL amyloidosis.
30. Bortezomib Maintenance Therapy as a Standard of Care Provides Favorable Outcomes in Newly Diagnosed Myeloma Patients: A Multisite Real-Life Study.
31. Thrombosis and Hemostasis Issues in Cancer Patients with COVID-19.
32. Flow cytometry aneuploidy and cell cycle indexing as a possible tool for differentiating between CD10+ diffuse large B‐cell lymphoma and follicular lymphoma.
33. Romidepsin treatment for relapsed or refractory peripheral and cutaneous T-cell lymphoma: Real-life data from a national multicenter observational study.
34. Characteristics, management and outcome of DLBCL patients, presenting with simultaneous systemic and CNS disease at diagnosis: A retrospective multicenter study.
35. Addition of high-dose methotrexate to standard treatment for patients with high-risk diffuse large B-cell lymphoma contributes to improved freedom from progression and survival but does not prevent central nervous system relapse.
36. Advances in the genetics of acute lymphoblastic leukemia in adults and the potential clinical implications.
37. Recovery from SARS-CoV-2 infection is associated with serum BDNF restoration.
38. Bone marrow blast elimination by the fifth day of 7 + 3 induction is the strongest predictor of potential cure in patients with acute myeloid leukemia younger than 61 years of age: A long‐term follow‐up of a multi‐center prospective study
39. Treatment and prognosis of stage I follicular lymphoma in the modern era - does PET matter?
40. Acute myeloid leukemia during pregnancy: a systematic review and meta-analysis.
41. Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/ CT is beneficial: a prospective multicentre trial of 355 patients.
42. Brain derived neurotropic factor single nucleotide polymorphism Val66Met and serum protein levels are associated with development of vincristine‐induced peripheral neuropathy in patients with lymphoma.
43. Prospective comparison of early bone marrow evaluation on day 5 versus day 14 of the "3+7" induction regimen for acute myeloid leukemia.
44. ABCL-366: Mosunetuzumab (Mosun) Monotherapy for Elderly/Unfit Patients with First-Line Diffuse Large B-Cell Lymphoma (DLBCL) Continues to Show Promising Safety and Efficacy with Durable Complete Responses.
45. Does Gender Matter in Non-Hodgkin Lymphoma? Differences in Epidemiology, Clinical Behavior, and Therapy.
46. Brain-derived neurotrophic factor in hematological malignancies: From detrimental to potentially beneficial.
47. Brain‐derived neurotrophic factor as a potential biomarker of chemotherapy‐induced peripheral neuropathy and prognosis in haematological malignancies; what we have learned, the challenges and a need for global standardization.
48. New Rising Infection: Human Herpesvirus 6 Is Frequent in Myeloma Patients Undergoing Autologous Stem Cell Transplantation after Induction Therapy with Bortezomib.
49. Thrombomodulin is a determinant of metastasis through a mechanism linked to the thrombin binding domain but not the lectin-like domain.
50. Thrombophilia and Cancer.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.